Cargando…

Ketogenic Diet in the Treatment of Gliomas and Glioblastomas

In recent years, scientific interest in the use of the ketogenic diet (KD) as a complementary approach to the standard cancer therapy has grown, in particular against those of the central nervous system (CNS). In metabolic terms, there are the following differences between healthy and neoplastic cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal Bello, Simone, Valdemarin, Francesca, Martinuzzi, Deborah, Filippi, Francesca, Gigli, Gian Luigi, Valente, Mariarosaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504425/
https://www.ncbi.nlm.nih.gov/pubmed/36145228
http://dx.doi.org/10.3390/nu14183851
_version_ 1784796212420935680
author Dal Bello, Simone
Valdemarin, Francesca
Martinuzzi, Deborah
Filippi, Francesca
Gigli, Gian Luigi
Valente, Mariarosaria
author_facet Dal Bello, Simone
Valdemarin, Francesca
Martinuzzi, Deborah
Filippi, Francesca
Gigli, Gian Luigi
Valente, Mariarosaria
author_sort Dal Bello, Simone
collection PubMed
description In recent years, scientific interest in the use of the ketogenic diet (KD) as a complementary approach to the standard cancer therapy has grown, in particular against those of the central nervous system (CNS). In metabolic terms, there are the following differences between healthy and neoplastic cells: neoplastic cells divert their metabolism to anaerobic glycolysis (Warburg effect), they alter the normal mitochondrial functioning, and they use mainly certain amino acids for their own metabolic needs, to gain an advantage over healthy cells and to lead to a pro-oncogenetic effect. Several works in literature speculate which are the molecular targets of KD used against cancer. The following different mechanisms of action will be explored in this review: metabolic, inflammatory, oncogenic and oncosuppressive, ROS, and epigenetic modulation. Preclinical and clinical studies on the use of KD in CNS tumors have also increased in recent years. An interesting hypothesis emerged from the studies about the possible use of a ketogenic diet as a combination therapy along with chemotherapy (CT) and radiotherapy (RT) for the treatment of cancer. Currently, however, clinical data are still very limited but encouraging, so we need further studies to definitively validate or disprove the role of KD in fighting against cancer.
format Online
Article
Text
id pubmed-9504425
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95044252022-09-24 Ketogenic Diet in the Treatment of Gliomas and Glioblastomas Dal Bello, Simone Valdemarin, Francesca Martinuzzi, Deborah Filippi, Francesca Gigli, Gian Luigi Valente, Mariarosaria Nutrients Review In recent years, scientific interest in the use of the ketogenic diet (KD) as a complementary approach to the standard cancer therapy has grown, in particular against those of the central nervous system (CNS). In metabolic terms, there are the following differences between healthy and neoplastic cells: neoplastic cells divert their metabolism to anaerobic glycolysis (Warburg effect), they alter the normal mitochondrial functioning, and they use mainly certain amino acids for their own metabolic needs, to gain an advantage over healthy cells and to lead to a pro-oncogenetic effect. Several works in literature speculate which are the molecular targets of KD used against cancer. The following different mechanisms of action will be explored in this review: metabolic, inflammatory, oncogenic and oncosuppressive, ROS, and epigenetic modulation. Preclinical and clinical studies on the use of KD in CNS tumors have also increased in recent years. An interesting hypothesis emerged from the studies about the possible use of a ketogenic diet as a combination therapy along with chemotherapy (CT) and radiotherapy (RT) for the treatment of cancer. Currently, however, clinical data are still very limited but encouraging, so we need further studies to definitively validate or disprove the role of KD in fighting against cancer. MDPI 2022-09-17 /pmc/articles/PMC9504425/ /pubmed/36145228 http://dx.doi.org/10.3390/nu14183851 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dal Bello, Simone
Valdemarin, Francesca
Martinuzzi, Deborah
Filippi, Francesca
Gigli, Gian Luigi
Valente, Mariarosaria
Ketogenic Diet in the Treatment of Gliomas and Glioblastomas
title Ketogenic Diet in the Treatment of Gliomas and Glioblastomas
title_full Ketogenic Diet in the Treatment of Gliomas and Glioblastomas
title_fullStr Ketogenic Diet in the Treatment of Gliomas and Glioblastomas
title_full_unstemmed Ketogenic Diet in the Treatment of Gliomas and Glioblastomas
title_short Ketogenic Diet in the Treatment of Gliomas and Glioblastomas
title_sort ketogenic diet in the treatment of gliomas and glioblastomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504425/
https://www.ncbi.nlm.nih.gov/pubmed/36145228
http://dx.doi.org/10.3390/nu14183851
work_keys_str_mv AT dalbellosimone ketogenicdietinthetreatmentofgliomasandglioblastomas
AT valdemarinfrancesca ketogenicdietinthetreatmentofgliomasandglioblastomas
AT martinuzzideborah ketogenicdietinthetreatmentofgliomasandglioblastomas
AT filippifrancesca ketogenicdietinthetreatmentofgliomasandglioblastomas
AT gigligianluigi ketogenicdietinthetreatmentofgliomasandglioblastomas
AT valentemariarosaria ketogenicdietinthetreatmentofgliomasandglioblastomas